June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
A Randomized, Phase I Dose-Escalation Study to Evaluate Tolerability, Safety and Pharmacokinetics (PK) of Trabodenoson in Healthy Older-Adult Volunteers
Author Affiliations & Notes
  • Alan Laties
    Ophthalmology, Univ of Pennsylvania Sch of Med, Philadelphia, PA
  • Randall Stoltz
    Covance, Evansville, IN
  • Chaim Brickman
    Inotek Corp., Lexington, MA
  • Vernon Humbert
    Evansville Heart Center, IN, Evansville, IN
  • N. Slomowitz
    Inotek Corp., Lexington, MA
  • William McVicar
    Inotek Corp., Lexington, MA
  • Rudolf Baumgartner
    Inotek Corp., Lexington, MA
  • Footnotes
    Commercial Relationships Alan Laties, AstraZeneca (C), Forest Research Inst (C), Kendle (C), Lilly (C), Merck (C), Pfizer (C), Sanofi-Aventis (C), TB Alliance for Drug Dev (C); Randall Stoltz, Covance (E); Chaim Brickman, Inotek Pharmaceuticals Corporation (E); Vernon Humbert, Inotek (C); N. Slomowitz, Inotek Pharmaceutical Corp (E); William McVicar, Inotek Pharmaceuticals (E); Rudolf Baumgartner, Inotek Pharm Corp (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 458. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alan Laties, Randall Stoltz, Chaim Brickman, Vernon Humbert, N. Slomowitz, William McVicar, Rudolf Baumgartner; A Randomized, Phase I Dose-Escalation Study to Evaluate Tolerability, Safety and Pharmacokinetics (PK) of Trabodenoson in Healthy Older-Adult Volunteers. Invest. Ophthalmol. Vis. Sci. 2013;54(15):458.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The safety, tolerability and PK of trabodenoson eye drops, a highly-selective adenosine-1 agonist, were assessed in healthy adult subjects.

Methods: In a Phase I unit, eligible adults after informed consent entered 1 of 7 sequential 10-subject cohorts (6 trabodenoson: 4 placebo). Cohorts 1-6 (Part 1) received monocular treatment with placebo or 200-3200 μg of trabodenoson BID for 14 days. Cohort 7 (Part 2) received step-wise escalating binocular doses of trabodenoson, from 1800-6400 μg total body dose. A single escalating dose (no punctual occlusion) was applied every 48 hrs to decrease the potential for systemic tolerance.

Results: 70 subjects (35-65 yrs) were randomized to placebo (n=28) or trabodenoson (n=42). The highest achievable dose (3200 µg per eye) was reached; no MTD was identified. No severe or study-drug-related serious AEs, or dose-limiting toxicities were reported. Systemic: Cardiovascular evaluations (heart rate, blood pressure, ECG, Holter and telemetry monitoring) showed no effect at any dose or time point. Troponin levels were normal in all subjects except for a transient elevation in one placebo subject. Pulmonary, CNS, and renal measurements showed no treatment-related effects. Ocular: Serial BCVA, IOP, and complete eye examinations elicited no safety signal. Ocular AEs, in Cohorts 1-6, were uncommon, self-limited, and usually mild with similar incidence for placebo (n=4; 14%) and active (n=6; 14%). Ocular hyperemia was reported in Part 1 in one subject (2.8%) (200μg dose, moderate, duration 1 hour and self-limited) and none in Part 2. In Part 2 there was one ocular AE - photophobia, reported in the placebo group. In Part 1, a small dose-dependent reduction in IOP was detected in several Cohorts (baseline IOP ~13 mmHg). PK: exposure to trabodenoson was dose-related with a plateau effect at the highest doses (at the 3 highest doses in Part 2, there was no increase in exposure with increasing dose). Median Tmax was 0.08 to 0.27 hrs and the mean t1/2 0.48 to 2.0 hrs across all doses. Drug did not accumulate in plasma following repeated administration.

Conclusions: Trabodenoson, up to the highest pragmatic achievable dose, was safe and well-tolerated. No MTD was identified. Trabodenoson had a short t1/2, no accumulation after repeated dosing, and limited systemic exposure.

Keywords: 568 intraocular pressure • 503 drug toxicity/drug effects • 427 aqueous  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.